8-K: Leap Therapeutics Secures Nasdaq Bid Price Extension

Leap Therapeutics, Inc. has received an additional 180-day grace period from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to March 9, 2026.

Summary

• Leap Therapeutics, Inc. received a notification from Nasdaq on March 12, 2025, regarding non-compliance with the minimum $1.00 closing bid price requirement (Rule 5550(a)(2)).
• The initial deadline to regain compliance was September 8, 2025, requiring the common stock to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
• On September 2, 2025, the company requested an additional 180-calendar day period and indicated its intent to cure the deficiency, potentially through a reverse stock split.
• Nasdaq granted an additional 180-calendar day period on September 10, 2025, extending the compliance deadline to March 9, 2026.
• The extension was granted because the company met the continued listing requirement for market value of publicly held shares and other applicable initial listing standards, excluding the bid price.
• The company must regain compliance with the minimum bid price requirement by March 9, 2026, or face delisting, with a potential appeal process available.

Sentiment

Score: 4

Explanation: The initial failure to meet Nasdaq's minimum bid price requirement is a negative event, indicating underlying stock performance issues. However, the granting of an extension provides a temporary reprieve and a path forward, albeit with significant uncertainty and the potential for a reverse stock split, which can be dilutive or perceived negatively by investors.

Positives

• Nasdaq granted an additional 180-calendar day period, extending the compliance deadline to March 9, 2026, providing more time to address the bid price deficiency.
• The company met the continued listing requirement for market value of publicly held shares and other applicable initial listing standards, which was a condition for receiving the extension.

Negatives

• The company failed to maintain the minimum $1.00 closing bid price for its common stock, leading to a non-compliance notification from Nasdaq.
• The initial 180-day compliance period expired without the company regaining compliance.
• There is no assurance that the company will be able to regain compliance with the bid price requirement or maintain compliance with other listing requirements during the extended period.

Risks

• Potential delisting of the company's common stock from The Nasdaq Capital Market if compliance with the minimum bid price requirement is not achieved by March 9, 2026.
• Risk of delisting for failure to maintain compliance with any other Nasdaq listing requirements during the additional 180-day period.
• Uncertainty regarding the effectiveness or timing of a potential reverse stock split to regain compliance.
• No assurance that an appeal to a Nasdaq Hearings Panel, if delisting occurs, would be successful.

Future Outlook

The company intends to closely monitor the closing bid price of its common stock and other listing requirements. It will consider plans for regaining compliance with Rule 5550(a)(2), including potentially implementing a reverse stock split. There is no assurance that compliance will be regained or maintained by the March 9, 2026 deadline.

Management Comments

• The company intends to monitor closely the closing bid price of its common stock, and the other listing requirements, and to consider plans for regaining compliance with Rule 5550(a)(2).
• The company may, if appropriate, consider implementing a reverse stock split of its outstanding common stock to regain compliance with the minimum bid price requirement.

Industry Context

NA

Stakeholder Impact

• Shareholders face potential delisting risk if the company fails to regain compliance, which could severely impact liquidity and valuation.
• Shareholders may experience a reduction in the number of shares held and a potential change in per-share value if a reverse stock split is implemented.

Next Steps

• Monitor the closing bid price of common stock and other Nasdaq listing requirements.
• Consider and potentially implement a reverse stock split to regain compliance with the minimum bid price requirement.
• Regain compliance with Nasdaq Listing Rule 5550(a)(2) by March 9, 2026.
• If compliance is not demonstrated, Nasdaq will provide written notification of delisting, at which point the company may appeal to a Hearings Panel.

Key Dates

Recommendation

While the company failed to meet the initial Nasdaq bid price requirement, the granting of a 180-day extension provides a critical window to rectify the situation. The potential for a reverse stock split is a known mechanism to address such issues, but its impact on long-term value and investor sentiment is uncertain. Given the temporary reprieve and the company's stated intent to regain compliance, an immediate 'sell' might be premature, but the inherent risks of delisting and the uncertainty surrounding the effectiveness of a reverse split warrant a 'hold' rather than a 'buy' until a clearer path to sustained compliance and operational improvement is demonstrated.

Keywords

Leap Therapeutics, LPTX, Nasdaq, Delisting, Bid Price, Compliance, Reverse Stock Split, SEC Filing, 8-K